INTRODUCTION: The impact of HIV infection and antiretroviral therapy (ART) on neurocognitive outcomes among children aged 7-14 years was assessed. We hypothesized that ART would ameliorate neurocognitive sequelae of HIV infection. METHODS: HIV-positive and HIV-negative mother-child pairs from the Rakai Community Cohort Study and ART clinics in Rakai, Uganda, were followed prospectively for 4 years. Exposures were stratified as: perinatally HIV infected, perinatally HIV exposed but uninfected, and HIV unexposed and uninfected. The Kaufman Assessment Battery for Children assessed sequential and simultaneous processing, learning, planning, knowledge, and fluid crystalized index for overall functioning. Multivariable generalized linear models estimated adjusted prevalence rate ratios by age. RESULTS: Of the 370 mother-child pairs, 55% were HIV unexposed and uninfected, 7% were perinatally HIV exposed but uninfected, and 37.9% were perinatally HIV infected. Among HIV-infected children, longer duration of ART was associated with a significant improvement of sequential processing skills (adjusted prevalence rate ratios 25-36 months: 0.55, 95% confidence interval [CI]: 0.34 to 0.9; 37-48 months: 0.39, 95% CI: 0.2 to 0.76; 49+ months: 0.23, 95% CI: 0.1 to 0.54). Each additional year of schooling was associated with a 30%-40% decrease of impairment for all neurocognitive measures assessed. Healthier children (higher age-standardized height and weight) had improved sequential and simultaneous processing and overall fluid crystalized index. CONCLUSIONS: Sequential processing skills of working memory improved with prolonged ART, and increased duration of schooling was associated with a reduction of neurocognitive impairment. Early initiation and sustained use of ARTs and longer schooling are needed to reduce neurocognitive impairment among HIV-infected school-aged children.
INTRODUCTION: The impact of HIV infection and antiretroviral therapy (ART) on neurocognitive outcomes among children aged 7-14 years was assessed. We hypothesized that ART would ameliorate neurocognitive sequelae of HIV infection. METHODS: HIV-positive and HIV-negative mother-child pairs from the Rakai Community Cohort Study and ART clinics in Rakai, Uganda, were followed prospectively for 4 years. Exposures were stratified as: perinatally HIV infected, perinatally HIV exposed but uninfected, and HIV unexposed and uninfected. The Kaufman Assessment Battery for Children assessed sequential and simultaneous processing, learning, planning, knowledge, and fluid crystalized index for overall functioning. Multivariable generalized linear models estimated adjusted prevalence rate ratios by age. RESULTS: Of the 370 mother-child pairs, 55% were HIV unexposed and uninfected, 7% were perinatally HIV exposed but uninfected, and 37.9% were perinatally HIV infected. Among HIV-infectedchildren, longer duration of ART was associated with a significant improvement of sequential processing skills (adjusted prevalence rate ratios 25-36 months: 0.55, 95% confidence interval [CI]: 0.34 to 0.9; 37-48 months: 0.39, 95% CI: 0.2 to 0.76; 49+ months: 0.23, 95% CI: 0.1 to 0.54). Each additional year of schooling was associated with a 30%-40% decrease of impairment for all neurocognitive measures assessed. Healthier children (higher age-standardized height and weight) had improved sequential and simultaneous processing and overall fluid crystalized index. CONCLUSIONS: Sequential processing skills of working memory improved with prolonged ART, and increased duration of schooling was associated with a reduction of neurocognitive impairment. Early initiation and sustained use of ARTs and longer schooling are needed to reduce neurocognitive impairment among HIV-infected school-aged children.
Authors: Michael J Boivin; Theodore D Ruel; Hannah E Boal; Paul Bangirana; Huyen Cao; Leigh A Eller; Edwin Charlebois; Diane V Havlir; Moses R Kamya; Jane Achan; Carolyne Akello; Joseph K Wong Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong Journal: Clin Infect Dis Date: 2012-02-04 Impact factor: 9.079
Authors: D Drotar; K Olness; M Wiznitzer; L Guay; L Marum; G Svilar; D Hom; J F Fagan; C Ndugwa; R Kiziri-Mayengo Journal: Pediatrics Date: 1997-07 Impact factor: 7.124
Authors: Manisha C Shanbhag; Richard M Rutstein; Theoklis Zaoutis; Huaqing Zhao; David Chao; Jerilynn Radcliffe Journal: Arch Pediatr Adolesc Med Date: 2005-07
Authors: Barbara Laughton; Morna Cornell; Debbie Grove; Martin Kidd; Priscilla E Springer; Els Dobbels; Anita J van Rensburg; Avy Violari; Abdel G Babiker; Shabir A Madhi; Patrick Jean-Philippe; Diana M Gibb; Mark F Cotton Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Isabel A Michaelis; Maryke Nielsen; Craig Carty; Markus Wolff; Caroline A Sabin; John S Lambert Journal: South Afr J HIV Med Date: 2020-06-30 Impact factor: 2.744
Authors: Michael J Boivin; Linda Barlow-Mosha; Miriam C Chernoff; Barbara Laughton; Bonnie Zimmer; Celeste Joyce; Mutsa Bwakura-Dangarembizi; Mmule Ratswana; Nasreen Abrahams; Lee Fairlie; Hermien Gous; Portia Kamthunzi; Katie McCarthy; Itziar Familiar-Lopez; Patrick Jean-Phillippe; Joan Coetzee; Avy Violari; Mark F Cotton; Paul E Palumbo Journal: AIDS Date: 2018-01-14 Impact factor: 4.177
Authors: Kaylee S van Wyhe; Tanya van de Water; Michael J Boivin; Mark F Cotton; Kevin Gf Thomas Journal: J Int AIDS Soc Date: 2017-06-14 Impact factor: 5.396
Authors: Megan K Suter; Catherine J Karr; Grace C John-Stewart; Laurén A Gómez; Hellen Moraa; Duke Nyatika; Dalton Wamalwa; Michael Paulsen; Christopher D Simpson; Niloufar Ghodsian; Michael J Boivin; Paul Bangirana; Sarah Benki-Nugent Journal: Int J Environ Res Public Health Date: 2018-01-20 Impact factor: 3.390
Authors: Paul Bangirana; Theodore D Ruel; Michael J Boivin; Satish K Pillai; Leila B Giron; Alla Sikorskii; Asish Banik; Jane Achan Journal: J Int AIDS Soc Date: 2017-10 Impact factor: 5.396